Cronexitide Lanocianine (CXL) with CancerVision® Goggles
Solid tumor visualization during surgery
Key Facts
About Integro Theranostics
Integro Theranostics is pioneering a targeted fluorescence imaging platform designed to make cancer cells visible during surgery, thereby enabling more complete tumor resections and reducing recurrence rates. Founded in 2019 and based in Philadelphia, the company is advancing its lead agent, CXL (formerly LS301), through clinical development alongside its proprietary CancerVision® Goggles and AI-powered data analytics tools. By focusing on real-time, intraoperative visualization, Integro aims to directly improve patient outcomes while also building a data ecosystem to optimize clinical trials. The company emphasizes a commitment to health equity, seeking to improve access and representation in oncology care and research.
View full company profile